Targeted therapy for biliary tract cancers

Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma

(2011) M Miyamoto et al.   BRITISH JOURNAL OF CANCER

An Uphill Battle Downstream of RAF

(2011) Eric A. Collisson   JOURNAL OF CLINICAL ONCOLOGY

Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers

(2011) Tanios Bekaii-Saab et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Dramatic Response to Panitumumab and Bevacizumab in Metastatic Gallbladder Carcinoma

(2011) E. Riley et al.   ONCOLOGIST

Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells

(2011) A. S. Little et al.   Science Signaling

Mutations in the RAS/RAF/MAP Kinase Pathway Commonly Occur in Gallbladder Adenomas But Are Uncommon in Gallbladder Adenocarcinomas

(2011) Rish K. Pai et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients

(2010) Rui Feng Xu et al.   BIOMEDICINE & PHARMACOTHERAPY

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas

(2010) Ymera Pignochino et al.   BMC CANCER

Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy

(2010) Zichen Zhang et al.   HEPATOLOGY

Genetics of Biliary Tract Cancers and Emerging Targeted Therapies

(2010) Aram F. Hezel et al.   JOURNAL OF CLINICAL ONCOLOGY

Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study

(2010) Sam J. Lubner et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study

(2010) Birgit Gruenberger et al.   LANCET ONCOLOGY

MET signalling: principles and functions in development, organ regeneration and cancer

(2010) Livio Trusolino et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation

(2010) R. B. Corcoran et al.   Science Signaling

Intrahepatic Cholangiocarcinoma

(2009) Itaru Endo et al.   ANNALS OF SURGERY

Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma

(2009) D Yoshikawa et al.   BRITISH JOURNAL OF CANCER

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial

(2009) C Bengala et al.   BRITISH JOURNAL OF CANCER

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

(2009) Ramesh K. Ramanathan et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Targeting the PI3K signaling pathway in cancer

(2009) Kwok-Kin Wong et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study

(2009) Andrew X Zhu et al.   LANCET ONCOLOGY

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

(2009) Jolien Tol et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma

(2008) Arne Westgaard et al.   BMC CANCER

RarePIK3CA hotspot mutations in carcinomas of the biliary tract

(2008) Marc-Oliver Riener et al.   GENES CHROMOSOMES & CANCER

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

(2008) J. Randolph Hecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Signaling networks assembled by oncogenic EGFR and c-Met

(2008) A. Guo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA